Comparative Pharmacology
Head-to-head clinical analysis: VITAMIN A PALMITATE versus VITAMIN A SOLUBILIZED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: VITAMIN A PALMITATE versus VITAMIN A SOLUBILIZED.
VITAMIN A PALMITATE vs VITAMIN A SOLUBILIZED
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Vitamin A palmitate is a retinoid that binds to retinoic acid receptors (RARs) and retinoid X receptors (RXRs), modulating gene transcription involved in cell growth, differentiation, and vision. It is converted to retinol and then to retinaldehyde and retinoic acid, essential for phototransduction, epithelial integrity, and immune function.
Vitamin A (retinol) is essential for vision, immune function, and cellular differentiation. It binds to nuclear retinoic acid receptors (RARs) and retinoid X receptors (RXRs), regulating gene transcription. In the retina, it forms rhodopsin, a light-sensitive pigment necessary for low-light vision.
Adult: 1,500-3,000 IU (450-900 mcg RAE) orally once daily for vitamin A deficiency; IM administration not recommended due to local toxicity.
Vitamin A solubilized: 10,000-50,000 IU orally once daily for deficiency. For severe deficiency: 100,000 IU intramuscularly once, repeated in 24 hours if needed. Maintenance: 10,000-20,000 IU orally daily.
None Documented
None Documented
Terminal elimination half-life is approximately 7–14 days for retinol in the liver; clinical effects persist for weeks due to extensive hepatic storage.
Terminal half-life: 12.5–60 days (mean ~25 days) in adults; prolonged in hypervitaminosis A. Clinical context: Accumulation risk with chronic use due to slow elimination.
Primarily hepatobiliary; >90% of retinol esters and metabolites excreted in feces via bile; less than 10% renally eliminated as water-soluble metabolites (e.g., retinoic acid glucuronides).
Renal: <1% as unchanged drug; biliary/fecal: >90% as metabolites and conjugated forms.
Category C
Category C
Vitamin A
Vitamin A